
Opinion|Videos|April 11, 2025
Recurrence Rates in Uncomplicated UTIs
Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for multidrug-resistant pathogens, inadequate personalized treatment approaches, minimal focus on biofilm disruption, lack of rapid point-of-care diagnostics to guide targeted therapy, poor understanding of the urinary microbiome’s role in infection susceptibility, and insufficient research into immunomodulatory interventions that could address the underlying mechanisms of recurrence and resistance development.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What gaps exist in current therapies for uncomplicated UTIs, particularly regarding the management of recurrence rates and the development of antibiotic resistance
Advertisement
Related to this article

Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.

An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.

Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.

Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
Advertisement
Advertisement
Trending on AJMC
1
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
2
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
3
How the GOLD 2026 Guidelines Updated COPD Diagnosis and Treatment
4
CF, Bronchiectasis Antimicrobial Resistance Varies Widely by Region
5


